<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations/><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/7E9697F0-2D75-4250-A46A-03919AC0BB65"><gtr:id>7E9697F0-2D75-4250-A46A-03919AC0BB65</gtr:id><gtr:name>Intercytex Limited</gtr:name><gtr:address><gtr:line1>78 CHORLEY NEW ROAD</gtr:line1><gtr:city>BOLTON</gtr:city><gtr:postCode>BL1 4BY</gtr:postCode><gtr:region>North West</gtr:region></gtr:address><gtr:typeInd>P</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/7E9697F0-2D75-4250-A46A-03919AC0BB65" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="gtr:organisationParticipantRole"><gtr:id>7E9697F0-2D75-4250-A46A-03919AC0BB65</gtr:id><gtr:name>Intercytex Limited</gtr:name><gtr:address><gtr:line1>78 CHORLEY NEW ROAD</gtr:line1><gtr:city>BOLTON</gtr:city><gtr:postCode>BL1 4BY</gtr:postCode><gtr:region>North West</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>PARTICIPANT</gtr:name></gtr:role><gtr:role><gtr:name>LEAD_PARTICIPANT</gtr:name></gtr:role></gtr:roles><gtr:offerGrant>137323.0</gtr:offerGrant><gtr:projectCost>183098.0</gtr:projectCost></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/5007E1C9-5CD9-45EF-88BA-93CF6F064BD0"><gtr:id>5007E1C9-5CD9-45EF-88BA-93CF6F064BD0</gtr:id><gtr:firstName>Paula</gtr:firstName><gtr:surname>Thompson</gtr:surname><gtr:roles><gtr:role><gtr:name>PROJECT_MANAGER</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=131275"><gtr:id>B0BE6256-7400-4323-B05D-16CC5E5DB29F</gtr:id><gtr:title>Feasibility of developing innovative processes to improve the manufacturing logistics of cell therapy</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Feasibility Studies</gtr:grantCategory><gtr:grantReference>131275</gtr:grantReference><gtr:abstractText>Cell Therapies hold the promise to treat a great many diseases, however one limiting feature of providing a living cell therapy is the realtively short shelf life of the products. This project aims to test the feasibility of using two different, innovative process changes to extend this shelf life considerably which would greatly impact how Intercytex's, and possibly others manufacture cell therapies. Success in this project will lead to additional studies by Intercytex to allow this process to be used for patient treatment. It will allow the Company to have product ready on demand for clinicans to treat the severe blistering disease Epidermolysis Bullosa and scar contractures.</gtr:abstractText><gtr:fund><gtr:end>2014-06-30</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/E18E2F0F-AC7D-4E02-9559-669F7C8FEC74"><gtr:id>E18E2F0F-AC7D-4E02-9559-669F7C8FEC74</gtr:id><gtr:name>Innovate UK</gtr:name></gtr:funder><gtr:start>2013-07-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>137323</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs/><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs/><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications/><gtr:identifiers><gtr:identifier type="RCUK">131275</gtr:identifier></gtr:identifiers><gtr:healthCategories/><gtr:researchActivities/><gtr:researchSubjects/><gtr:researchTopics><gtr:researchTopic><gtr:id>D05BC2E0-0345-4A3F-8C3F-775BC42A0819</gtr:id><gtr:text>Unclassified</gtr:text></gtr:researchTopic></gtr:researchTopics><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>